Schumacher Laura J Form 4 December 07, 2018

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

**OMB APPROVAL** 

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

response...

burden hours per

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Schumacher Laura J

(First)

2. Issuer Name and Ticker or Trading Symbol

(Middle)

5. Relationship of Reporting Person(s) to

Issuer

AbbVie Inc. [ABBV]

(Check all applicable)

1 N. WAUKEGAN ROAD

3. Date of Earliest Transaction (Month/Day/Year)

\_X\_\_ Officer (give title

10% Owner Other (specify

12/04/2018

below)

**Executive Vice President** 

6. Individual or Joint/Group Filing(Check

(Street) 4. If Amendment, Date Original

Applicable Line)

Director

\_X\_ Form filed by One Reporting Person

Filed(Month/Day/Year)

Form filed by More than One Reporting

Person

NORTH CHICAGO, IL 60064

| (City)                               | (State)                                 | (Zip) Tak   | ole I - Non-                           | Derivative | Secu  | rities Acquii        | red, Disposed of,  | or Beneficiall   | y Owned   |
|--------------------------------------|---|---|--|------------|---|----------------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactic<br>Code<br>(Instr. 8) | omr Dispos | Securities Acquired (A) r Disposed of (D) nstr. 3, 4 and 5)  (A) or |                      | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
| Common stock, \$0.01 par value       | 12/04/2018                              |   | M                                      |            | (D)   | Price \$ 51.42       | 192,398  | D  |   |
| Common stock, \$0.01 par value       | 12/04/2018                              |   | S                                      | 33,198     | D   | \$<br>94.3418<br>(1) | 159,200  | D  |   |
| Common stock, \$0.01 par value       | 12/04/2018                              |   | S                                      | 41,642     | D   | \$<br>93.6647<br>(2) | 117,558  | D  |   |

#### Edgar Filing: Schumacher Laura J - Form 4

| Common stock, \$0.01 par value | 12/04/2018 | S | 10,000 | D | \$<br>92.3705<br>(3) | 107,558 | D |
|--------------------------------|------------|---|--------|---|----------------------|---------|---|
| Common stock, \$0.01 par value | 12/04/2018 | S | 9,300  | D | \$<br>91.7745<br>(4) | 98,258  | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) |     |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                     |
|---|---|--------------------------------------|---|-----|--------|--|--------------------|---|-------------------------------------|
|   |   |                                      | Code V                                  | (A) | (D)    | Date<br>Exercisable                                      | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of Shares |
| Option (Right to                                    | \$ 51.42  | 12/04/2018                           | M                                       |     | 94,140 | 02/20/2015   | 02/19/2024         | Common<br>Stock   | 94,140                              |

## **Reporting Owners**

| Reporting Owner Name / Address |          |           | Relationships                   |       |  |  |
|--------------------------------|----------|-----------|---------------------------------|-------|--|--|
| <b></b>                        | Director | 10% Owner | Officer                         | Other |  |  |
| Schumacher Laura J             |          |           |                                 |       |  |  |
| 1 N. WAUKEGAN ROAD             |          |           | <b>Executive Vice President</b> |       |  |  |
| NORTH CHICAGO, IL 60064        |          |           |                                 |       |  |  |

# **Signatures**

buy) (5)

Steven L. Scrogham, attorney-in-fact for Laura J.
Schumacher 12/07/2018

\*\*Signature of Reporting Person

Reporting Owners 2

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.98 to \$94.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.00 to \$93.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.98 to \$92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.515 to \$92.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (5) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

#### **Remarks:**

The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.